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Purpose or Objective: Purpose: To analyze feasibility and 
toxicity of radical hypofractionated RT schedules in elderly 
patients with NSCLC 
 
Material and Methods: Material and methods: Elderly 
patients (≥70 years old) affected by stage III inoperable 
NSCLC were treated in our institution with radical IMRT 
(VMAT RA) according to moderately hypofractionated 
schedules: 56 Gy/20 fractions or 55 Gy/22 fractions or 50 
Gy/20 fractions depending on dose constraints of adjacent 
organs at risk. Patients underwent simulation CT in supine 
position, immobilized with a thermoplastic mask. PET CT was 
performed for simulation and coregistered with CT. Primary 
end point of this analysis were acute and late toxixcities, 
secondary end points were local control and overall survival. 
 
Results: Results: 41 patients, treated between January 2013 
and April 2015, were included in this analysis. Mean age was 
78.59 years (range 70-86). 22 patients were staged IIIA, 19 
patients IIIB. All but one patients had pathological nodal 
involvement (N1:5, N2: 24, N3: 11). Most of patients were 
unsuitable for chemotherapy for comorbidities and poor 
general conditions. 15 patients received chemotherapy 
before RT, concomitant RT-CHT was not allowed. Acute G1-2 
toxicity was recorded in 25 patients(61), mostly esophagitis, 
dyspnea and dry cough. Late toxicity was recorded in 13 
patients, the most reported side effects were pneumonitis 
and dyspnea. No G3 or G4 acute or late toxicity were 
recorded. A complete response was obtained in two patients, 
26 showed a partial response, while progressive disease was 
recorded in 2 cases. At time of analysis, with a mean follow 
up of 9.89 months (range 1.08-25.43), 17 patients died for 
disease progression, one patient died for other causes, 8 
patients were alive with distant metastases and 15 were alive 
without distant progression. Actuarial OS at 1 and 2 years 
were 51.3% and 35.1% respectively. Mean estimated OS was 
15.12 months (range 12.02-18.22). Actuarial local control at 1 
and 2 years were 72%. 10 patients experienced local 
progression. Mean estimated LC was 12.4 months (range 9.6-
15.1). 
 
Conclusion: Conclusion: Radical hypofractionated IMRT 
(VMAT RA) is a valid treatment for locally advanced 
inoperable NSCLC in elderly frail patients . Our study shows 
that this approach is safe and feasible also in a fragile elder 
population. Survival data are satisfactory. 
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Purpose or Objective: To assess the efficacy and safety of a 
SHort-course Accelerated RadiatiON therapy (SHARON) 
regimen in the palliative treatment of locally advanced or 
metastatic cancers in elderly patients.  
 
Material and Methods: Eligibility criteria of this analysis 
(pooled analysis of 3 phase II studies) were: patients with 
histologically confirmed solid cancers, age ≥ 80 years, 
patients with an expected survival > 3 months and Eastern 
Cooperative Oncology Group (ECOG) performance status of ≤ 
3. The primary endpoint was to evaluate the symptoms 
response rate produced by a radiotherapy regimen based on 
the delivery of 4 radiotherapy fractions (5 Gy per fraction) 
with a twice daily fractionation in two consecutive days 
 
Results: Twenty-four patients were included in this analysis. 
Characteristics of the patients were: male/female: 17/7; 
median age: 87.0 years (range: 80-98). ECOG performance 
status was < 3 in 16 patients (66.7%). Six patients (25.0%) had 
locally advanced thoracic cancers, 13 patients (54.2%) had 
advanced primary or metastatic H&N tumors and 5 patients 
(20.8%) had complicated bone metastases. With a median 
follow-up time of 5.0 months (range, 1 to 8 months), eleven 
G1-G2 acute skin (45.9%) and G1-2 mucositis (12.5%) 
toxicities were recorded. One patient (4.2%) experienced G1 
acute gastro-intestinal toxicity and only 1 patient (4.2%) 
experienced G3 acute mucositis. Of 24 symptomatic patients, 
19 showed an improvement or resolution of baseline 
symptoms (overall palliative response rate: 79.2%). Three-
months overall survival was 89.7% (median survival time: 7.0 
months; 95%CI 5.4-8.6 mo). Median survival without 
symptoms progression was 5.0 months (95%CI: 2.5-7.5 mo). In 
23 patients with pain, a significant reduction of this symptom 
was recorded in terms of VAS (mean baseline VAS vs mean 
VAS after treatment: 3.9 versus 1.7, p=0.001).  
 
Conclusion: Short-course accelerated radiotherapy in locally 
advanced or metastatic cancers is effective in terms of 
symptom relief and well tolerated even in older patients. 
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Purpose or Objective: The optimal treatment of bladder 
cancer has been a subject of continuous controversy. In North 
America, as well as in Europe, the radical cistectomy as the 
standard option for invasive bladder cancer. In the western 
countries the elderly ones constitute the part of the 
population in more rapid growth and, insofar, the group to 
